How does "pattern care" differ from "step therapy"? Does the bionic pancreas work? Why is incretin therapy taking off? Here, a 5-slide review of these and other hot topics from the 2014 ADA Scientific Sessions.
Posters at ADA 2014 showcased growing popularity of the incretin therapies and SGLT2 inhibitors. Most fascinating to this diabetologist blogger was use of insulin and a GLP-1 RA in a fixed-combination product.
Activation of opioid receptors with novel approaches may prevent hypoglycemia and lead to safer intensive glycemic control, according to a study reported at the American Diabetes Association 74th Scientific Sessions.